Investigating the mechanism of Rehmannia glutinosa-Ephedra sinica in heart failure with preserved ejection fraction by network pharmacology, metabolomics and experimental validation.

ETHNOPHARMACOLOGICAL RELEVANCE: Rehmannia glutinosa and Ephedra sinica (MD), herbs from the classical formula Yanghe Decoction, have been used to nourish yin, enrich blood and promote diuresis. Their traditional indications, which include chest tightness and edema, closely parallel the clinical manifestations of heart failure with preserved ejection fraction (HFpEF).

AIM OF THE STUDY: To evaluate the therapeutic efficacy of MD in HFpEF and explore its mechanisms, particularly lipid peroxidation and ferroptosis inhibition.

MATERIALS AND

METHODS

The chemical composition of MD was characterized by UPLC-Q-TOF-MS. HFpEF was induced in C57BL/6 mice by a high-fat diet combined with N^ω-nitro-L-arginine methyl ester. MD effects were evaluated by metabolic parameters, cardiac function, histopathology, and lipid and lipid peroxidation markers. Network pharmacology and metabolomics identified potential targets and pathways. H9C2 cells were stimulated with palmitic acid and treated with MD-containing serum, with additional interventions using LY294002 and RSL3. The predicted signaling mechanisms were further verified in both in vivo and in vitro models by Western blotting.

RESULTS

MD improved metabolic disorders, cardiac remodeling, and diastolic dysfunction, and reduced myocardial injury and lipid peroxidation. Mechanistic analyses indicated PI3K/AKT signaling and ferroptosis regulation via GPX4/ACSL4. In vitro, MD-containing serum attenuated palmitic acid-induced metabolic dysfunction and ferroptosis, effects partly abolished by LY294002 and RSL3.

CONCLUSION

MD exerts cardioprotective effects in HFpEF by modulating metabolic dysfunction and ferroptosis, which may be associated with the activation of the PI3K/AKT and GPX4/ACSL4 pathways.